Andrew E. Schade

5.5k total citations · 1 hit paper
48 papers, 1.1k citations indexed

About

Andrew E. Schade is a scholar working on Molecular Biology, Immunology and Genetics. According to data from OpenAlex, Andrew E. Schade has authored 48 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 14 papers in Immunology and 9 papers in Genetics. Recurrent topics in Andrew E. Schade's work include Angiogenesis and VEGF in Cancer (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Complement system in diseases (4 papers). Andrew E. Schade is often cited by papers focused on Angiogenesis and VEGF in Cancer (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Complement system in diseases (4 papers). Andrew E. Schade collaborates with scholars based in United States, Sweden and Australia. Andrew E. Schade's co-authors include Alan D. Levine, Jaroslaw P. Maciejewski, Marcin W. Włodarski, Hadrian Szpurka, Anna Jankowska, Vojkan Susulic, Robert Townsend, Rosemary Zhang, Gary L. Schieven and Timothy R. Holzer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Andrew E. Schade

45 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

2022 138 citations Michael J. Pontecorvo, Andrew E. Schade et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew E. Schade United States	16	354	305	239	225	221	48	1.1k
Jack Shi United States	13	396 1.1×	247 0.8×	394 1.6×	228 1.0×	203 0.9×	19	1.1k
Andrej Skerjanec Switzerland	19	332 0.9×	705 2.3×	669 2.8×	65 0.3×	132 0.6×	44	1.9k
Sujata Arora United States	15	169 0.5×	297 1.0×	534 2.2×	72 0.3×	219 1.0×	41	1.4k
Suzanne J.A. Korporaal Netherlands	22	258 0.7×	341 1.1×	171 0.7×	59 0.3×	288 1.3×	51	1.5k
Gurjeet Bhangal United Kingdom	20	353 1.0×	401 1.3×	83 0.3×	106 0.5×	75 0.3×	32	1.2k
Swaminathan Murugappan United States	15	129 0.4×	336 1.1×	382 1.6×	114 0.5×	458 2.1×	27	1.3k
Naoya Mimura Japan	23	207 0.6×	901 3.0×	366 1.5×	104 0.5×	555 2.5×	84	1.8k
Toshiyuki Kitano Japan	18	234 0.7×	782 2.6×	536 2.2×	86 0.4×	139 0.6×	70	1.6k
SJ Lauer United States	16	80 0.2×	586 1.9×	176 0.7×	153 0.7×	321 1.5×	19	1.6k
Keith Abe United States	14	112 0.3×	354 1.2×	197 0.8×	134 0.6×	291 1.3×	16	997

Countries citing papers authored by Andrew E. Schade

Since Specialization

Citations

This map shows the geographic impact of Andrew E. Schade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew E. Schade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew E. Schade more than expected).

Fields of papers citing papers by Andrew E. Schade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew E. Schade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew E. Schade. The network helps show where Andrew E. Schade may publish in the future.

Co-authorship network of co-authors of Andrew E. Schade

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew E. Schade. A scholar is included among the top collaborators of Andrew E. Schade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew E. Schade. Andrew E. Schade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lu, Ming‐Chi, Amanda Sheffield Morris, Rose Beck, et al.. (2025). Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease. The Journal of Applied Laboratory Medicine. 10(3). 533–545. 4 indexed citations

Hodsdon, Michael E., Ming‐Chi Lu, Amanda Sheffield Morris, et al.. (2024). Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT). Alzheimer s & Dementia. 20(S8).

Gruver, Aaron M., Haiyan Lu, Xiaoxian Zhao, et al.. (2023). Pathologist-trained machine learning classifiers developed to quantitate celiac disease features differentiate endoscopic biopsies according to modified marsh score and dietary intervention response. Diagnostic Pathology. 18(1). 122–122. 6 indexed citations

Munsie, Leanne, Adam Fleisher, M. Stauffer, et al.. (2023). Use of plasma P‐tau217 for enrichment in the Phase 2 PROSPECT‐ALZ study of LY3372689 in early symptomatic Alzheimer’s disease: Cohort selection and baseline characteristics. Alzheimer s & Dementia. 19(S21).

Ackermann, Bradley L., Ryan D. Morrison, Matthew D Westfall, et al.. (2023). Targeted Quantitative Mass Spectrometry Analysis of Protein Biomarkers From Previously Stained Single Formalin-Fixed Paraffin-Embedded Tissue Sections. Laboratory Investigation. 103(4). 100052–100052. 3 indexed citations

Dougan, Marcelle, Ajay Nirula, Robert Gottlieb, et al.. (2021). Bamlanivimab+etesevimab for treatment of COVID-19 in high-risk ambulatory patients. 29(1). 33–33. 6 indexed citations

Cohen, Max, Ajay Nirula, Mary Marovich, et al.. (2021). Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting. 29(1). 32–33. 4 indexed citations

Liebler, D.C., Ryan D. Morrison, Robbert J.C. Slebos, et al.. (2020). Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry. Laboratory Investigation. 100(6). 874–886. 22 indexed citations

Liebler, D.C., Timothy R. Holzer, Ryan D. Morrison, et al.. (2020). Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer. Scientific Reports. 10(1). 9805–9805. 19 indexed citations

10.

Walk, Eric, Sophia Yohe, Andrew E. Schade, et al.. (2019). The Cancer Immunotherapy Biomarker Testing Landscape. Archives of Pathology & Laboratory Medicine. 144(6). 706–724. 61 indexed citations

11.

Nasir, Aejaz, et al.. (2017). Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies. Cancer Cell International. 17(1). 56–56. 25 indexed citations

12.

Jankowska, Ania, Hadrian Szpurka, Maria Grazia Calabró, et al.. (2011). Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria. Haematologica. 96(7). 954–962. 9 indexed citations

13.

Osinbowale, Olusegun, Monzr M. Al Malki, Andrew E. Schade, & John R. Bartholomew. (2009). An algorithm for managing warfarin resistance. Cleveland Clinic Journal of Medicine. 76(12). 724–730. 31 indexed citations

14.

Gibson, Sarah E., Andrew E. Schade, Hadrian Szpurka, et al.. (2008). Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F. Human Pathology. 39(7). 1111–1114. 9 indexed citations

15.

Szpurka, Hadrian, Andrew E. Schade, Anna Jankowska, & Jaroslaw P. Maciejewski. (2008). Altered lipid raft composition and defective cell death signal transduction in glycosylphosphatidylinositol anchor‐deficient PIG‐A mutant cells. British Journal of Haematology. 142(3). 413–422. 14 indexed citations

16.

Downs‐Kelly, Erinn, Andrew E. Schade, & Donna E. Hansel. (2007). The role of HLA-G in gastrointestinal inflammatory disease and malignancy. Seminars in Cancer Biology. 17(6). 451–458. 9 indexed citations

17.

Schade, Andrew E., Marcin W. Włodarski, & Jaroslaw P. Maciejewski. (2006). Pathophysiology Defined by Altered Signal Transduction Pathways: The Role of JAK-STAT and PI3K Signaling in Leukemic Large Granular Lymphocytes. Cell Cycle. 5(22). 2571–2574. 35 indexed citations

18.

Włodarski, Marcin W., Andrew E. Schade, & Jaroslaw P. Maciejewski. (2006). T-large granular lymphocyte leukemia: current molecular concepts. Hematology. 11(4). 245–256. 24 indexed citations

19.

Schade, Andrew E. & Alan D. Levine. (2004). Cutting Edge: Extracellular Signal-Regulated Kinases 1/2 Function as Integrators of TCR Signal Strength. The Journal of Immunology. 172(10). 5828–5832. 30 indexed citations

20.

Schade, Andrew E. & Alan D. Levine. (2002). Signal transduction through the T cell receptor is dynamically regulated by balancing kinase and phosphatase activities. Biochemical and Biophysical Research Communications. 296(3). 637–643. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact